Syensqo (SYENS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
15 May, 2026Executive summary
Net sales reached EUR 1.4 billion in Q1 2026, up 5% sequentially but down 7% year-over-year, with growth led by Specialty Polymers and Novecare; volumes were stable year-on-year.
Underlying EBITDA was EUR 251 million (17.9% margin), up 6.5% sequentially but down 17% year-over-year.
Gross margin was resilient at 31.7%, up 260 bps sequentially but down 110 bps year-over-year.
The sale of the Oil & Gas business was completed in January, generating EUR 130 million in net proceeds.
Leadership changes and targeted programs were launched to accelerate growth and address underperformance.
Financial highlights
Net sales of EUR 1.4 billion, up 5% sequentially but down 7.4% year-over-year; underlying EBITDA of EUR 251 million, up 6% sequentially but down 17% year-over-year.
Gross profit for Q1 2026 was EUR 444 million, gross margin 31.7%, up 260 bps sequentially.
Operating cash flow was EUR 82 million in Q1, impacted by working capital and project costs; full-year operating cash flow expected at EUR 700 million.
CapEx for the quarter was EUR 97 million, down 44% year-over-year; full-year CapEx outlook reduced by up to EUR 50 million to EUR 450 million.
Net debt at EUR 2.0 billion, gearing ratio 24%, leverage ratio 1.7x; EUR 500 million bond redeemed.
Outlook and guidance
Full-year 2026 underlying EBITDA and operating cash flow outlook remain unchanged at approximately EUR 1.1 billion and EUR 700 million, with Q1 expected to be the lowest quarter.
Gradual recovery in volumes anticipated through the year, especially in Composite Materials and Electronics.
Capital expenditure guidance lowered to EUR 450 million for 2026.
Sequential improvement in Q2 and further step-up in Q3 expected to meet full-year guidance.
Impact from Middle East conflict expected to be limited, with mitigation actions in place.
Latest events from Syensqo
- 2025 saw lower sales and profit but higher free cash flow; 2026 set for modest volume growth.SYENS
Q4 20259 Apr 2026 - Record financials, innovation, and bold sustainability targets defined the meeting.SYENS
AGM 20243 Feb 2026 - Q2 saw sequential growth but year-over-year declines, with CapEx delayed and cash flow hit by settlement.SYENS
Q2 20242 Feb 2026 - Q2 2025 sales and EBITDA fell YoY, but margin gains and stable 2025 outlook were maintained.SYENS
Q2 202521 Jan 2026 - Margins and cash flow held firm despite lower sales, with specialty focus and divestment ongoing.SYENS
Q3 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Strong 2024 results, higher returns, and accelerated innovation amid global challenges.SYENS
AGM 202521 Nov 2025